MEAI

MEAI
Clinical data
Other names	5-MeO-AI; 5-MeO-2-AI; 5-Methoxy-2-aminoindane; 5-Methoxy-2-aminoindan; Methoxyaminoindane; Chaperon; Pace; CMND-100; CMND100
Routes of; administration	Oral, Intranasal
Drug class	Serotonin–norepinephrine releasing agent (SNRA); Selective serotonin releasing agent (SSRA); Psychoactive drug; Entactogen
ATC code	None;
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act; In general: unscheduled;
Identifiers
	IUPAC name 5-methoxy-2-aminoindane;
CAS Number	73305-09-6 ;
PubChem CID	12147687;
ChemSpider	11591017;
UNII	AD8S15863A;
CompTox Dashboard (EPA)	DTXSID80478566 ;
Chemical and physical data
Formula	C10H13NO
Molar mass	163.220 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC2=C(CC(C2)N)C=C1;
	InChI InChI=1S/C10H13NO/c1-12-10-3-2-7-4-9(11)5-8(7)6-10/h2-3,6,9H,4-5,11H2,1H3; Key:HLXHCNWEVQNNKA-UHFFFAOYSA-N;

MEAI, also known as 5-methoxy-2-aminoindane (5-MeO-AI) and by its developmental code name CMND-100, is an entactogen-like psychoactive drug of the 2-aminoindane family. It is a cyclized phenethylamine and is the 2-aminoindane analogue of 3-methoxyamphetamine. The drug acts as a serotonin–norepinephrine releasing agent (SNRA) or as a modestly selective serotonin releasing agent (SSRA), with about 6-fold preference for induction of serotonin over norepinephrine release. MEAI has been encountered as a novel designer recreational drug. It is also under development for potential medical use in the treatment of alcoholism, cocaine use disorder, metabolic syndrome, and obesity.